January 1, 2012Thrombosis and Haemostasis
The use of rivaroxaban for short- and long-term treatment of venous thromboembolism
Key result
Rivaroxaban was non-inferior to standard of care for recurrent VTE in acute DVT and superior to placebo for extended-duration prevention of recurrent VTE.
Why the study?
Does rivaroxaban reduce recurrent VTE in patients with acute DVT or prior VTE treatment?
Population
Patients with acute deep-vein thrombosis without pulmonary embolism and patients with confirmed DVT or PE…
Comparison
Rivaroxaban (oral, once-daily) vs Standard of care in EINSTEIN DVT; placebo in…
Design
Review, randomised
Authors
Discussion
Loading...
Member takes
Implication
Rivaroxaban offers convenient oral VTE therapy without monitoring; extends RCT evidence favoring DOACs over VKAs in practice.
Structured PICO
Does rivaroxaban reduce recurrent VTE in patients with acute DVT or prior VTE treatment?
P
Population
Patients with acute deep-vein thrombosis (DVT) without pulmonary embolism (PE) (EINSTEIN DVT) and patients with confirmed DVT or PE who had received 6-12 months of prior VTE treatment (EINSTEIN EXT)
I
Intervention
Rivaroxaban (oral, once-daily)
C
Comparator
Standard of care (enoxaparin plus a vitamin K antagonist) in EINSTEIN DVT; placebo in EINSTEIN EXT
O
Outcome
Recurrent VTEhard clinical
This review highlights that rivaroxaban provides an effective, simplified, once-daily oral regimen for both initial treatment and extended prevention of VTE.
Cite This Study
Cohen et al. (2012) conducted a review in Venous thromboembolism (VTE). Rivaroxaban vs. Standard of care (enoxaparin plus a vitamin K antagonist) or placebo was evaluated on Recurrent VTE. Rivaroxaban was non-inferior to standard of care for recurrent VTE in acute DVT and superior to placebo for extended-duration prevention of recurrent VTE.